ALX Oncology Holdings Inc.ALXONASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 1.17% |
| Q3 2025 | -3.22% |
| Q2 2025 | -24.56% |
| Q1 2025 | 1.51% |
| Q4 2024 | -11.10% |
| Q3 2024 | -23.61% |
| Q2 2024 | 9.26% |
| Q1 2024 | -24.09% |
| Q4 2023 | -8.70% |
| Q3 2023 | 55.23% |
| Q2 2023 | 19.06% |
| Q1 2023 | -1.72% |
| Q4 2022 | -14.24% |
| Q3 2022 | 9.85% |
| Q2 2022 | 56.67% |
| Q1 2022 | -18.29% |
| Q4 2021 | 14.71% |
| Q3 2021 | 62.44% |
| Q2 2021 | 13.85% |
| Q1 2021 | -18.88% |
| Q4 2020 | 127.89% |
| Q3 2020 | -30.47% |
| Q2 2020 | 100.18% |
| Q1 2020 | -43.16% |
| Q4 2019 | 204.75% |
| Q3 2019 | -39.08% |
| Q2 2019 | -2.81% |
| Q1 2019 | 0.00% |